SIG
46
2
M
58
5
ZION
71
2
MTCH
59
9
GM
85
2
MMC
53
-5
CMCSA
44
-2
XEL
37
-2
NFLX
40
3
JBHT
65
2
RIG
40
2
STI
18
11
BAX
38
-12
RSG
47
2
ALLE
44
3
V
52
2
AN
50
7
DTE
38
-4
IP
28
-3
PFE
33
-8
SIG
46
2
M
58
5
ZION
71
2
MTCH
59
9
GM
85
2
MMC
53
-5
CMCSA
44
-2
XEL
37
-2
NFLX
40
3
JBHT
65
2
RIG
40
2
STI
18
11
BAX
38
-12
RSG
47
2
ALLE
44
3
V
52
2
AN
50
7
DTE
38
-4
IP
28
-3
PFE
33
-8
Financhill
Back

Kalaris Therapeutics, Inc. 10K Form

Buy
61

KLRS
Kalaris Therapeutics, Inc.

Last Price:
$9.95
Seasonality Move:
-37.32%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KLRS News And Ratings

See the #1 stock for the next 7 days that we like better than KLRS

KLRS Financial Statistics

Sales & Book Value

Annual Sales: $0
Cash Flow: $-11.5M
Price / Cash Flow: 0
Annual Sales: $2.24
Price / Book: 4.08

Profitability

EPS (TTM): -7.39730
Net Income (TTM): $-51.7M
Gross Margin: $0
Return on Equity: -65.74%
Return on Assets: -49.89%

Kalaris Therapeutics, Inc. Earnings Forecast

Key Kalaris Therapeutics, Inc. Financial Ratios

  • Per Share Earnings over the last 7 years have been positive in 3 years.

Kalaris Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Current Symbol: KLRS
Website: kalaristx.com

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 12.89
Quick Ratio: 12.7

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KLRS Technical Analysis vs Fundamental Analysis

Buy
61
Kalaris Therapeutics, Inc. (KLRS) is a Buy

Is Kalaris Therapeutics, Inc. a Buy or a Sell?